Symphogen

Results: 16



#Item
1January 8, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. 1. Baxalta, Symphogen Ink $1.6 Billion Immuno­Oncology Deal In yet

January 8, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. 1. Baxalta, Symphogen Ink $1.6 Billion Immuno­Oncology Deal In yet

Add to Reading List

Source URL: www.dcat.org

Language: English - Date: 2016-01-11 11:16:23
2Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology  Partnership aims to advance development of novel immune checkpoint

Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology  Partnership aims to advance development of novel immune checkpoint

Add to Reading List

Source URL: sunstone.eu

Language: English - Date: 2016-01-04 04:51:17
    3Symphogen Enters into strategic collaboration with Genentech for antibody therapeutics SYMPHOGEN ENTERS INTO STRATEGIC COLLABORATION WITH GENENTECH FOR ANTIBODY THERAPEUTICS IN INFECTIOUS DISEASE COPENHAGEN, Denmark –

    Symphogen Enters into strategic collaboration with Genentech for antibody therapeutics SYMPHOGEN ENTERS INTO STRATEGIC COLLABORATION WITH GENENTECH FOR ANTIBODY THERAPEUTICS IN INFECTIOUS DISEASE COPENHAGEN, Denmark –

    Add to Reading List

    Source URL: sunstone.eu

    Language: English - Date: 2014-10-27 08:46:29
    4

    PDF Document

    Add to Reading List

    Source URL: dwl.gov-online.go.jp

    Language: English - Date: 2013-04-04 10:31:40
    5FOR  IMMEDIATE  RELEASE     Theraclone  Sciences’  I-­‐STAR™  Technology  Chosen  by  Wellcome  Trust     to  Identify  Therapeutic  Antibodies  Against  Ebol

    FOR  IMMEDIATE  RELEASE     Theraclone  Sciences’  I-­‐STAR™  Technology  Chosen  by  Wellcome  Trust     to  Identify  Therapeutic  Antibodies  Against  Ebol

    Add to Reading List

    Source URL: www.theraclone-sciences.com

    Language: English - Date: 2015-04-30 08:07:06
    6Molecular Engineering The Molecular Engineering laboratory focuses on development and application of Darwinian in vitro selection technologies, allowing the generation of novel recombinant antibodies. Today the global ma

    Molecular Engineering The Molecular Engineering laboratory focuses on development and application of Darwinian in vitro selection technologies, allowing the generation of novel recombinant antibodies. Today the global ma

    Add to Reading List

    Source URL: eng.au.dk

    Language: English - Date: 2015-02-02 10:36:34
    7  PRESS RELEASE: Bioceros B.V. announces change of ownership Utrecht, The Netherlands, February 17th, Bioceros B.V. announces that it has successfully realized a change of ownership. This is the result of the pu

      PRESS RELEASE: Bioceros B.V. announces change of ownership Utrecht, The Netherlands, February 17th, Bioceros B.V. announces that it has successfully realized a change of ownership. This is the result of the pu

    Add to Reading List

    Source URL: thujacapital.com

    Language: English - Date: 2011-11-06 02:53:53
    8Advancing the Frontier of Antibody Therapeutics Kirsten Drejer, PhD Chief Executive Officer

    Advancing the Frontier of Antibody Therapeutics Kirsten Drejer, PhD Chief Executive Officer

    Add to Reading List

    Source URL: www.symphogen.com

    Language: English - Date: 2014-01-14 13:28:11
    9MORPHODOMA® Technology: Enhancing Antibody Titers

    MORPHODOMA® Technology: Enhancing Antibody Titers

    Add to Reading List

    Source URL: www.morphotek.com

    Language: English - Date: 2011-02-26 01:00:51
    10[removed]Zymeworks_Merck_Expansion_Extension

    [removed]Zymeworks_Merck_Expansion_Extension

    Add to Reading List

    Source URL: www.biotech.ca

    Language: English - Date: 2014-12-09 09:56:32